Cat. No. | Product name | CAS No. |
DCC4996 |
Szv558
Potent inhibitor of both rodent and human MAO-B, proved to be safe in high doses with no hERG and mutagenic activities and demonstrated neuroprotection in an in vivo chronic model of PD |
1648929-13-8 |
DCC4997 |
T0511-4424
Novel COX-2 inhibitor |
882215-85-2 |
DCC4998 |
T-0632
Potent and selective CCKA receptor antagonist |
169042-78-8 |
DCC4999 |
T-10106
Novel potent PPARγ antagonist with much improved drug-like properties and promising pharmacokinetic profile |
|
DCC5000 |
T16a(inh)-b01
Selective class B inhibitor of the Ca -activated Cl- Channel, Ano1(TMEM16A) |
708246-07-5 |
DCC5001 |
T16a(inh)-d01
Selective class D inhibitor of the Ca -activated Cl- Channel, Ano1(TMEM16A) |
874129-53-0 |
DCC5002 |
T-2 Toxin Triol
Type-A trichothecene mycotoxin |
97373-21-2 |
DCC5003 |
T3ss Inhibitor Iii-7
Novel inhibitor of the type III secretion system (T3SS), acting as a anti-microbial agent against Xanthomonas oryzae pv. oryzae (Xoo) |
|
DCC5004 |
t5660136
Novel Inhibitor of Adenovirus Gene Transfer |
920852-86-4 |
DCC5005 |
t5660138
Novel Inhibitor of Adenovirus Gene Transfer |
920882-18-4 |
DCC5006 |
T5975164
Inhibitor of HIV-1 Assembly that Targets the Phosphatidylinositol (4,5)-bisphosphate Binding Site of the HIV-1 Matrix Protein |
949860-27-9 |
DCC5007 |
T6603185
Novel inhibitor of the catalytic functions of peroxiredoxin (Prx) and thioredoxin (Trx) systems |
1208822-03-0 |
DCC5008 |
Tachioside
Natural radical scavenger on ABTS |
109194-60-7 |
DCC5009 |
Tachyplegina
Novel Inhibitor of Parasite Motility and Invasion |
331839-29-3 |
DCC5010 |
Tachyplegina-2
Novel Inhibitor of Parasite Motility and Invasion |
296798-88-4 |
DCC5011 |
Tachyplegina-4
Novel Irriversible Inhibitor of Parasite Motility and Invasion |
|
DCC5012 |
Tacrine-pyrimidone Hybrid 27g
Novel Potent Dual AChE/GSK-3 Inhibitor for the Treatment of Alzheimers Disease |
|
DCC5013 |
Tah-19
Novel potent p53-MDM2/X antagonist, inhibiting MDM2 potently with a Ki value of 58 nmol/L, inducing accumulation of p53, p21 and MDM2, inhibiting cell cycle progression of U-2 OS cells at G1 phase in a p53-dependent manner |
|
DCC5014 |
Ta-in-2
Novel inhibitor of the Klebsiella pneumoniae VapBC toxin-antitoxin (TA) system, acting as antimicrobial agents by disrupting the VapBC complex and activating VapC |
|
DCC5015 |
Tak-137
Novel AMPA receptor potentiator with little agonistic effect, producing antidepressant-like effect without causing psychotomimetic effects |
1358749-55-9 |
DCC5016 |
tak-187
Long-lasting ergosterol biosynthesis inhibitor |
155432-64-7 |
DCC5017 |
Tak-21d
Potent FAAH Inhibitor |
1143578-94-2 |
DCC5018 |
Tak-220 Hydrochloride
Novel anti-HIV CCR5 antagonist |
674782-27-5 |
DCC5019 |
Tak-233
Novel selective 5-hydroxytryptamine type 2C (5-HT2C) receptor agonist |
|
DCC5020 |
Tak-418
Novel inhibitor of the epigenetic modulator lysine-specific demethylase 1A (LSD1) |
1818252-53-7 |
DCC5021 |
Talaroconvolutin A
Natural ferroptosis inducer, killing colorectal cancer cells in vitro and in vivo |
273199-42-1 |
DCC5022 |
Talarozole
CYP26 inhibitor, potentiating the effects of all-trans retinoic acid on cultured human epidermal keratinocytes |
201410-53-9 |
DCC5023 |
Talaumidin
Natural neurotrophic agent, promoting neurite outgrowth from neurons through PI3K/Akt pathway |
|
DCC5024 |
Talirine
Novel Antibody-Drug Conjugate PBD Dimer Payload |
1342820-51-2 |
DCC5025 |
Taltirelin
Superagonist at the human thyrotropin-releasing hormone receptor, reversing opioid-induced respiratory depression in isoflurane anesthetized rats |
103300-74-9 |
DCC5026 |
Tamra-edatp
Novel Fluorescent dATP for DNA Synthesis In Vivo, exhibited high brightness, low toxicity, and rapid incorporation and depletion kinetics in both a vertebrate (zebrafish) and a nematode (Caenorhabditis elegans) |
|
DCC5027 |
Tan-67
Potent and selective non-peptide δ1 opioid receptor agonist |
148545-09-9 |
DCC5028 |
Tanshinol Borneol Ester
Novel angiogenesis stimulator, promoting multiple key steps of angiogenesis parially via Akt and MAPK signalling pathways, showing anti-ischemic and anti-atherosclerosis activities, also acting as a putative PPARγ agonist |
|
DCC5029 |
Tap1a-opt1
Novel potent Na V -targeting peptide, exhibiting significant increased potency for Na V 1.1, Na V 1.2, Na V 1.3, Na V 1.6 and Na V 1.7 involved in several neurological disorders including acute and chronic pain, motor neuron disease and epilepsy |
|
DCC5030 |
Tap1a-opt2
Novel potent Na V -targeting peptide, exhibiting significant increased potency for Na V 1.1, Na V 1.2, Na V 1.3, Na V 1.6 and Na V 1.7 involved in several neurological disorders including acute and chronic pain, motor neuron disease and epilepsy |
|
DCC5031 |
Tapi-2 Acetate
ADAM-17 (TACE) and MMP inhibitor, sensitizing cancer stem cells to the lethal effects of 5-FU and blocking shedding of TNF-α from cell membranes |
689284-12-6 |
DCC5032 |
Tariquidar Dimesylate
Potent P-glycoprotein (P-gp) inhibitor |
625375-84-0 |
DCC5033 |
Tas-303 Hydrochloride
Novel selective norepinephrine reuptake inhibitor, displaying significant norepinephrine transporter (NET) inhibitory activity toward the serotonin or dopamine transporters |
|
DCC5034 |
tasidotin Hydrochloride
Tubulin-binding dolastatin-15 analog, demostrating a wide spectrum of In Vivo antitumor activity |
623174-20-9 |
DCC5035 |
Tasp0233278
Potent and orally active V 1B receptor antagonist with antidepressant and anxiolytic activities in rodents |
|
DCC5036 |
Tasp0277308
Potent and selective sphingosine 1-phosphate 1 (S1P1) receptor antagonist (IC50 = 7.8 nM) |
945725-50-8 |
DCC5037 |
Tasp0412098
Novel potent, selective, and orally active CRTH2 antagonist |
1233248-29-7 |
DCC5038 |
Tat Peptide (47-57)
Trans-activator of transcription (TAT) peptide, increasing Hepta-histidine (7H) permeability into cells for treatment of iPS cell-derived neurons carrying Tau or APP mutations suppressed Tau phosphorylation |
191936-91-1 |
DCC5039 |
Tat-gap19
Novel brain penetrant Cx43 hemichannel blocker |
1507930-54-2 |
DCC5040 |
Tavarua Deoxyriboside A
Potential neuroprotective agent, showing effects on cellular models of oxidative stress and neuroinflammation |
|
DCC5041 |
Tazanolast
Selective mast-cell-stabilizing agent, inhibiting ozone-induced airway hyperresponsiveness |
82989-25-1 |
DCC5042 |
Tb-2-081
Novel antagonist of IL-6 signaling |
451470-55-6 |
DCC5043 |
Tbbl-0000316
Novel antibiotic against Mycobacterium tuberculosis (Mtb), potently killing replicating, virulent Mtb H37Rv in a clavulanate-dependent manner |
|
DCC5044 |
Tbdps-chc
Novel potent MCT1 inhibitor, exhibiting good single agent anticancer efficacy properties |
|
DCC5045 |
Tbe-31
Highly potent activator of Nrf2; Potent phase 2 cytoprotective pathway inducer and liver carcinogenesis blocker |
936475-62-6 |
DCC5046 |
Tbk1 Inhibitor-1
Novel TBK1/IKKε inhibitor |
|
DCC5047 |
Tbz-07
Novel anti-angiogenesis and vascular disrupting agent, exhibiting moderate inhibitory cell proliferation activity |
875468-82-9 |
DCC5048 |
Tbz-19
Novel anti-angiogenesis and vascular disrupting agent, exhibiting moderate inhibitory cell proliferation activity |
|
DCC5049 |
Tc299423
Novel agonist for nicotinic acetylcholine receptors (nAChRs), modestly selectively targeting α6β2 subtype |
1975146-56-5 |
DCC5050 |
Tc-ac28
Novel potent and selective ligand of Brd2(2) |
1809296-92-1 |
DCC5051 |
Tc-aqp1-1
Aquaporin 1 (AQP1) channel blocker |
37710-81-9 |
DCC5052 |
tc-c-14g
Potent CB1 receptor inverse agonist |
656804-72-7 |
DCC5053 |
Tc-e 5006
Novel orally bioavailableγ-secretase modulator, reducing Aβ42 levels |
1257395-14-4 |
DCC5054 |
FPR Agonist 43
Featured
FPR Agonist 43 (compound 43) is a dual formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)/ALX agonist. |
903895-98-7 |
DCC5055 |
Tc-g1004
Potent and selective antagonist of adenosine A2A receptors |
1061747-72-5 |
DCC5056 |
Tch-013
Non-competitive modulator of the proteasome inducing apoptosis a panel of myeloma and leukemia cell lines |
1132091-17-8 |
DCC5057 |
Tc-i 2000
Novel TRPM8 channel blocker |
1150006-20-9 |
DCC5058 |
Tc-i 2014
Potent TRPM8 antagonist, exhibiting antiallodynic properties in pain models |
1221349-53-6 |
DCC5059 |
tcmdc-125802
Antimalarial; Novel inhibitor of HepG2 |
1060-19-1 |
DCC5060 |
Tcmdc-135051 Tfa Salt
Novel Inhibitor of the malaria parasite protein kinase CLK3, inhibiting the development of liver-stage parasites, killing asexual blood-stage parasites at the trophozoite and schizont stages of the erythrocytic cycle, blocking the development of sexual ga |
2413716-15-9 |
DCC5061 |
Tcn-237 Dihydrochloride
Highly potent NR2B-selective NMDA receptor antagonist |
700878-19-9 |
DCC5062 |
Tc-ot-39
Nonpeptide partial agonist of oxytocin (OT) and vasopressin V2 receptors |
479232-57-0 |
DCC5063 |
Tc-s 7005
Potent and selective polo-like kinase 2 (PLK2) inhibitor |
1082739-92-1 |
DCC5064 |
Tcs2312
Novel potent and selective CHK1 kinase inhibitor |
838823-31-7 |
DCC5065 |
Tcs2314
Novel Integrin very late antigen-4 (VLA-4; α4β1) antagonist, blocking the activation of inflammatory cells. |
317353-73-4 |
DCC5066 |
Tcs-3035
Novel GPR35 agonist |
871085-49-3 |
DCC5067 |
Tcs-401
Insulin receptor sensitizing agent; Selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B) |
243967-42-2 |
DCC5068 |
Tc-t 6000
Potent equilibrative nucleoside transporter 4 (ENT4) inhibitor |
949467-71-4 |
DCC5069 |
T-cupm
Sorafenib analogue, retaining cytotoxicity similar to sorafenib in various human cancer cell lines and strongly inhibiting growth in the NCI-60 cell line panel |
|
DCC5070 |
Td-004
Novel degrader of the anaplastic lymphoma kinase (ALK) fusion protein, effectively inducing ALK degradation and inhibiting the growth of ALK fusion positive cell lines, SU-DHL-1 and H3122, significantly reducing the tumor growth in H3122 xenograft model |
|
DCC5071 |
Td-106
Novel IKZF1/3 degrader, inhibiting the proliferation of multiple myeloma cells in vitro as well as in vivo |
2250288-69-6 |
DCC5072 |
Td-1211
Novel selective opioid receptor antagonist at all three receptor types |
949904-48-7 |
DCC5073 |
Td-428
Novel potent BET protein degrader, inhibiting cell proliferation due to suppressed C-MYC transcription |
2334525-50-5 |
DCC5074 |
Td-5471 Hydrochloride
Novel long-acting β 2 -adrenoceptor agonist |
530084-35-6 |
DCC5075 |
Tdcipp
Hepatotoxicity inducer, significantly up-regulating the expression of genes involved in endoplasmic reticulum stress and Toll-like receptor (TLR) pathway |
13674-87-8 |
DCC5076 |
Tdmq20
Novel Specific Copper Chelator, Reducing Memory Impairments in Alzheimer's Disease Mouse Models |
|
DCC5077 |
Tdp1-in-9a
Novel potent inhibitor of tyrosyl-DNA phosphodiesterase 1 (Tdp1) |
|
DCC5078 |
Tdp222669
Novel inhibitor of the p53-Hdm2 protein-protein interaction, dose-dependently stabilized P53 and increased P21 and MDM2 expression in JAR choriocarcinoma cells, inducing the p53 regulated gene (PIG-3) and caspase activity |
879484-94-3 |
DCC5079 |
Tdr32570
Novel antimalarial agent |
1428183-45-2 |
DCC5080 |
Tecovirimat Hydrate
Featured
Novel inhibitor of viral p37, blocking the ability of virus particles to be released from infected cells, being used for the treatment of smallpox, monkeypox, orthopoxvirus, and orthopoxviral Disease. |
1162664-19-8 |
DCC5081 |
Tefinostat
Novel monocyte/macrophage targeted histone deacetylase inhibitor |
914382-60-8 |
DCC5082 |
Teijin Compound 1 Hydrochloride
CCR2b receptor antagonist |
226226-39-7 |
DCC5083 |
Teixobactin
Natural antibacterial agent, being active against gram-positive bacteria. |
1613225-53-8 |
DCC5084 |
Telenzepine
Potent and selective M1 antimuscarinic |
80880-90-6 |
DCC5085 |
Telmesteine
Mucolitic agent, inhibiting activation of nuclear factor kappa-κB (NF-κB) by blocking phosphoinositide 3-kinase/protein kinase B (PI3K/Akt)/IκB kinase (IKK) activities, showing the anti-inflammatory properties on inflammation-associated skin diseases |
122946-43-4 |
DCC5086 |
Temoporfin
Photosensitizing agent used in the treatment of squamous cell carcinoma of the head and neck, also showing activity agaimst COVID-19 Mpro |
122341-38-2 |
DCC5087 |
Tenidap Sodium
COX/5-LOX inhibitor and cytokine-modulating anti-inflammatory agent |
119784-94-0 |
DCC5088 |
Tertomotide
Peptide vaccine, residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), for the treatment of solid cancers |
915019-08-8 |
DCC5089 |
Terutroban Sodium
Selective Thromboxane_receptor>thromboxane receptor antagonist |
609340-89-8 |
DCC5090 |
Tet3.0
Mutually Orthogonal Bioorthogonal Amino Acid, Enabling Efficient Protein Dual-Labeling in Cells |
|
DCC5091 |
Tetrabenazine
Reversible inhibitor of vesicular monoamine transporter 2, showing anti-chorea effect and decreasing uptake of monamines into synaptic vesicles, as well as depletion of monoamine storage |
718635-93-9 |
DCC5092 |
Tetrabromobisphenol A
Activator of the hepatic interferon pathway in rats |
79-94-7 |
DCC5093 |
Tetracenomycin X
Potent inhibitor of protein synthesis, inhibiting translation by binding within the ribosomal exit tunnel |
121245-07-6 |
DCC5094 |
Tetrazanbigen
Inducer of S phase arrest and apoptosis in hepatocellular carcinoma QGY-7701 |
|
DCC5095 |
Texaline
Antitubercular agent |
115070-72-9 |
DCC5096 |
Texasin
Potent and selective human leukocyte 5-lipoxygenase (5-LOX) inhibitor |
897-46-1 |
DCC5097 |
Tezosentan
Novel endothelin (ET) receptor antagonist |
180384-57-0 |
DCC5098 |
Tfah-10n
Novel multipotent anti-Alzheimer agent, selectively inhibiting human butyrylcholinesterase (BChE), having strong antioxidant activity and good β-amyloid (Aβ) anti-aggregation properties |
|
DCC5099 |
Tfgf-18
Novel GSK-3β inhibitor, showing anti-neuroinflammatory effects in lipopolysaccharide (LPS) activation of spontaneously immortalized SIM-A9 microglial cells and of mouse cortical microglia, inhibiting LPS-induced production of nitric oxide and the proinfla |
|
DCC5100 |
Tfmo-1
Novel cell-active, selective class IIa HDAC inhibitor |
|
DCC5101 |
Tfmo-12
CNS-penetrant selective class IIa histone deacetylase (HDAC) inhibitor, exploiting the >100-fold selectivity over class I/IIb HDACs |
|
DCC5102 |
Tfr4oht
Cyclized tamoxifen analog, selective ER modulator (SERM) |
113748-88-2 |
DCC5103 |
Tg-0054
Novel and Potent Stem Cell Mobilizer; Inhibitor of SDF-1α/CXCR4 binding |
1191448-17-5 |
DCC5104 |
Tg-0205221
Novel potent SARS coronavirus (CoV) 3CL protease inhibitor (Ki = 53 nM) |
|
DCC5105 |
Tg100948
Novel dual VEGFR/Src kinase inhibitor |
1001341-27-0 |
DCC5106 |
Tg101114
Novel inhibitor of T315I mutant enzyme, exhibiting reasonable in vivo efficacy in a xenograft mouse model harboring T315I |
937013-83-7 |
DCC5107 |
Tg11-77 Hydrochloride
Novel, Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist |
|
DCC5108 |
Tg-2112x
Novel inhibitor of mitochondrial calcium uptake (#333333; font-family: "Open Sans", HelveticaNeue, "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 15px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: |
|
DCC5109 |
Tg2-in-3h
Highly selective, potent, cell-permeable fluorescent irreversible tissue transglutaminase (TG2) inhibitor |
1592640-75-9 |
DCC5110 |
Tg3-95-1
EP2 allosteric potentiator |
301322-12-3 |
DCC5111 |
Tg4-166
Potent and selective nociceptin opioid receptor (NOP) agonist |
1164541-81-4 |
DCC5112 |
tg4-290-1
Potent and selective nociceptin opioid receptor (NOP) agonist |
1415604-18-0 |
DCC5113 |
tg4-292-1
Potent and selective nociceptin opioid receptor (NOP) agonist |
1415602-18-4 |
DCC5114 |
Tg4-294-2
Potent and Selective Antagonist for Human EP2 Receptors |
1415602-08-2 |
DCC5115 |
Tgp-200c
Novel potent and structure-specific inhibitor of pre-miR-200c, reversing a type 2 diabetes phenotype |
|
DCC5116 |
Tgr5 Agonist 11d-na
Novel potent TGR5 agonist, displayind a significant glucose-lowering effect and stimulated GLP-1 and insulin secretion in TGR5H88Y mice but not in wild-type animals |
|
DCC5117 |
Tgr5-agonist-17
Novel Potent Agonist of TGR5 Receptor |
|
DCC5118 |
Tgx-115
Cell-permeable, potent, and selective inhibitor of PI 3-K isoforms p110ß/p110d |
351071-62-0 |
DCC5119 |
Tgx-155
Potent and selective inhibitor of PI 3-K |
351071-90-4 |
DCC5120 |
Th1027
Novel highly potent and specific inhibitor of TLR8, targeting an unconventional pocket on the TLR8 protein-protein Interface |
|
DCC5121 |
Thaigranatin T
Natural potent human carboxylesterase 2 (hCES2) inhibitor (IC50: 5.05 μM) |
|
DCC5122 |
Thalassosamide
Natural antibiotic, being active against P. aeruginosa both in vitro and in vivo. |
|
DCC5123 |
Thdp-17
Novel glutaminase activity inhibitor, showing a partial uncompetitive inhibition in vitro and a significant reduction of ammonia and glutamate production in vivo |
104741-27-7 |
DCC5124 |
Thiamphenicol Palmitate
Prodrug of Thiamphenicol, inhibiting the 50S subunit of the bacterial ribosome and protein translation |
52628-58-7 |
DCC5125 |
Thiazolidinedione-8
Novel antibiofilm agent, disturbing symbiotic balance between C. albicans and S. mutans in dual species biofilm |
|
DCC5126 |
Thidiazuron
Highly efficient bioregulator of plant morphogenesis in the tissue culture technique, inducing diverse responses ranging from induction of callus to embryogenesis or organogenesis, acting through modulation of the endogenous plant growth regulators, modif |
51707-55-2 |
DCC5127 |
Thielocin B1
Novel protein-protein interaction inhibitor of PAC3 homodimer |
144118-26-3 |
DCC5128 |
Thiobenzanilide 63t
Novel selective anticancer agent, selectively inducing cancer cell death in a caspase independent pathway |
1270966-08-9 |
DCC5129 |
Thiocrom-31
First-in-class potent, selective, reversible, and tight binding inhibitor of human monoamine oxidase B (hMAO-B) (hMAO-B IC 50 = 1.52 ± 0.15 nM) |
|
DCC5130 |
Thioguanine-18
Novel potent DENV2-NS2B/NS3pro inhibitor |
|
DCC5131 |
Thioluciferin
Firefly luciferin analog as a key element of bioluminescent reporters for oxidation state and thiol/disulfide equilibria |
|
DCC5132 |
Thiomuscimol Hydrobromide
GABAA receptor agonist |
62020-54-6 |
DCC5133 |
Thiowurtzine
Novel Potent Inhibitor of the Opioid Receptors and the Ion Channels |
|
DCC5134 |
Thioxodihydroquinazolinone-19
Novel inducer of apoptotic cell death in platinum-resistant A2780cis human ovarian cancer cells, exhibitong a strong inhibitory effect in ovarian CSC-LCs in combination with cisplatin |
177951-34-7 |
DCC5135 |
Thiq-20c
Steroidomimetic and Chimeric Microtubule Disruptor |
|
DCC5136 |
Thk-523
Selective Tau ligand, selectively binding to neurofibrillary tangles and neuropils in people with Alzheimer's disease |
1573029-17-0 |
DCC5137 |
Th-pf01
Novel orthosteric-allosteric dual inhibitor of PfHT1 as selective antimalarial agent |
|
DCC5138 |
Th-pf02
Novel orthosteric-allosteric dual inhibitor of PfHT1 as selective antimalarial agent |
|
DCC5139 |
Th-pf03
Novel orthosteric-allosteric dual inhibitor of PfHT1 as selective antimalarial agent |
|
DCC5140 |
Thpp-11f
Novel potent, highly selective and orally available PI3Kδ inhibitor |
|
DCC5141 |
Thpp-2
Novel phosphodiesterase 10A (PDE10A) inhibitor for treatment of schizophrenia |
1393750-01-0 |
DCC5142 |
Thpp-4
Phosphodiesterase 10A (PDE10A) inhibitor |
1257051-56-1 |
DCC5143 |
Thr101
Novel dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9; NOX Inhibitor |
727664-79-1 |
DCC5144 |
Thrombin-in-3g
Novel selective thrombin inhibitor, inducing conformational allostery |
|
DCC5145 |
Thrx160209
Novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor |
|
DCC5146 |
Tiagabine
Anti-epileptic and anticonvulsant agent, acting as a selective GABA reuptake inhibitor |
115103-54-3 |
DCC5147 |
Tiancimycin
Anthraquinone-fused enediyne antitumor agent for development of antibody-drug conjugates (ADCs) |
|
DCC5148 |
Tiemonium Iodide
Muscarinic receptor antagonist, anticholinergic,and parasympatholytic |
6252-92-2 |
DCC5149 |
Tigilanol Tiglate
Natural anticancer agent fortreatment of mast cell tumor (MCT) |
943001-56-7 |
DCC5150 |
Tillman Reagent
Widely used oxidation-reduction indicator |
620-45-1 |
DCC5151 |
Tilmicosin Phosphate
Macrolide antibiotic for the treatment of bovine respiratory disease and ovine respiratory disease associated with Mannheimia (Pasteurella) haemolytica |
137330-13-3 |
DCC5152 |
Tilorone Dihydrochloride
Antiviral, antineoplastic, and anti-inflammatory agent; Orally active interferon inducer, inhibiting Ebola virus (EBOV) |
27591-69-1 |
DCC5153 |
Tinostamustine Hydrochloride
Novel pan-histone-deacetylase inhibitor with alkylating activity |
1793059-58-1 |
DCC5154 |
Tinyatoxin
Neurotoxin, acting via vanilloid receptors of sensory nerves |
58821-95-7 |
DCC5155 |
Tioxolone
Novel hepcidin antagonist |
4991-65-5 |
DCC5156 |
tipp-204
hPPAR |
943544-10-3 |
DCC5157 |
tipp-401
Dual PPA |
876296-16-1 |
DCC5158 |
tipp-703
hPPAR-pan agonist |
1016893-72-3 |
DCC5159 |
Tiracizine Hydrochloride
Anti-arrhythmia agent |
78816-67-8 |
DCC5160 |
Tl13-117
Novel AC220-based FLT3 degrader |
|
DCC5161 |
Tl13-149
Novel AC220-based FLT3 degrader |
|
DCC5162 |
Tli3-12
The first small molecule degrader, inducing anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines |
|
DCC5163 |
Tli3-i12
The first small molecule degrader, inducing anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines |
|
DCC5164 |
Tlk19781
Novel Insulin Receptor Modulator |
309932-60-3 |
DCC5165 |
tlr4-in-c35
Novel Toll-Like Receptor 4 (TLR4) Inhibitor |
21559-74-0 |
DCC5166 |
Tlr7/8-in-cmpd2
Novel potent and selective dual TLR7/8 inhibitor |
|
DCC5167 |
Tlr8-in-5
Novel toll-like receptor 8 (TLR8) inhibitor, potently and selectively reducing TLR8-mediated signaling |
|
DCC5168 |
Tls-in-5
The first small molecule inhibitor of translesion synthesis (TLS) that target Rev1-CT |
|
DCC5169 |
Tm2-119
Potent histone methyltransferase inhibitor with rapid antimalarial activity against all blood stage forms in Plasmodium falciparum |
1238673-02-3 |
DCC5170 |
Tm-233
Novel inhibitor of both JAK/STAT and proteasome activities, inducing cell death in myeloma cells |
1103745-28-3 |
DCC5171 |
Tm5001
Novel inhibitor of plasminogen activator inhibitor-1 (PAI-1) |
342595-03-3 |
DCC5172 |
Tma-230
Penem beta-lactam antibiotic |
113141-80-3 |
DCC5173 |
Tmc-310911
Novel protease inhibitor (PI) against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to generate resistance, also showing antiviral avtivity as a potential treatment for COVID-19 caused by SARS-CoV-2 |
1000287-05-7 |
DCC5174 |
Tm-p4-thal
Dual Inhibitor of SIRT2 Deacetylase and Defatty-Acylase Activities |
|
DCC5175 |
Tmp-b3a
Novel degrader of E. coli DHFR (eDHFR), as well as eDHFR-EGFP fusion proteins, demonstrating that degradation does not require covalent attachment of the tag to the target protein |
|
DCC5176 |
Tmp-nvoc-halo
Novel caged protein labeling agent |
|
DCC5177 |
Tmppaa
Allosteric agonist and positive allosteric modulator (PAM) of 5-HT3 receptor |
844900-50-1 |
DCC5178 |
Tmq0153
Novel activator of necrostatin-1 sensitive necroptotic cell death, triggering apoptosis, autophagy and necroptosis crosstalk in chronic myeloid leukemia |
|
DCC5179 |
Tnfalpha-in-4e
Novel potent inhibitor of TNF-α |
|
DCC5180 |
Tnfalpha-in-5783168
Novel inhibitor of tumor necrosis factor-α (TNF-α) |
|
DCC5181 |
Tnk-6123
Emivirine analog with improved activity against drug-resistant HIV mutants |
251481-69-3 |
DCC5182 |
Tnk-651
Novel non-nucleoside reverse transcriptase inhibitor of HIV-1 |
175739-42-1 |
DCC5183 |
Tnks/usp25-in-c44
Novel selective inhibitor of TNKS-USP25 interaction, effectively reducing prostate cancer cell proliferation and tumor growth |
|
DCC5184 |
Tnks2-in-5
Novel highly potent and selective TNKS2 inhibitor with antiproliferative effects in a colorectal cancer cell line (DLD-1) where the Wnt pathway is constitutively activated |
|
DCC5185 |
Tnks-in-1
Highly potent and selective tankyrase inhibitor |
59455-93-5 |
DCC5186 |
Tnks-in-21
Novel potent and selective tankyrase (TNKS) inhibitor |
1498300-35-8 |
DCC5187 |
Tnp-2092
Unique multitargeting drug conjugate with extremely low propensity for development of resistance, targeting RNA polymerase, DNA gyrase, and DNA topoisomerase IV |
922717-97-3 |
DCC5188 |
Tol8-agonist-31a
Novel Human Toll-like Receptor 8-Selective Agonist |
|
DCC5189 |
Toldimfos Sodium
Stimulator of metabolism, preventing diseases associated with parturition and peri-partum period, developmental and nutritional disorders in young animals, and bone growth disorders and tetany or paresis caused by calcium, magnesium, and phosphorus metabo |
575-75-7 |
DCC5190 |
Tonantzitlolone
Natural agonist of TPRC1/4/5 channels, also acting as a dual PKCα and PKCθ activator, inducing an insulin resistant phenotype by inhibiting IRS1 and the PI3K/Akt pathway, activating the heat shock factor 1 (HSF1) transcription factor driving glucose depen |
845811-30-5 |
DCC5191 |
Top1/tdp1-in-c12
Novel dual TOP1 and TDP1 inhibitor, inducing both cellular TOP1cc, TDP1cc formation and DNA damage, resulting in cancer cell apoptosis at a sub-micromolar concentration |
|
DCC5192 |
Top1210
Novel narrow spectrum kinase inhibitor, potently inhibiting P38a, Src, and Syk kinase activities |
1628439-59-7 |
DCC5193 |
Top-dnj
Novel Selective Inhibitor of Endoplasmic Reticulum α-Glucosidase II, Exhibiting Antiflaviviral Activity |
1508303-85-2 |
DCC5194 |
Topki-nbd
Novel highly specific fluorescent TOPK inhibitor |
|
DCC5195 |
To-pro3 Iodide
Nucleic acid stain, acting on viable, early apoptotic and necrotic cells differentially, showing specific staining of nuclei without any staining of the cytoplasm |
157199-63-8 |